Dinutuximab

N/A

Report date: 2026/03/06 20:02:51
First In Class

Base Information

Drug NameDinutuximab
Drug Alias Name达妥昔单抗Chimeric anti-GD2 monoclonal antibodyAnti-GD2 monoclonal antibody ch14.18地努妥昔单抗Unituxin +[7] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibody
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsComplement dependent cytotoxicity (CDC) effectsDisialoganglioside GD2 inhibitors
TargetsDisialoganglioside GD2
Therapy Area/IndicationsGanglioneuroblastomaNeuroblastoma
Global Approved IndicationsNeuroblastoma
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2015/03/10
Country/TerritoryCanadaUnited StatesPuerto Rico +[7] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesNational Cancer Institute
China Registration ClassN/A

Develop Information

Active CompaniesNational Cancer InstituteAbbvie IncUnited Therapeutics Corp +[4] 
Inactive CompaniesUnited Therapeutics Europe Ltd
Active IndicationsGanglioneuroblastomaNeuroblastoma
Inactive IndicationsN/A

Other Information

ATC CodeL01XC16
Related LinksWikipediaDrugBankKEGG